Search PubMed⌕ Search

Biomedical subjects

C Diehm

Publications and source records attributed to C Diehm.

At least 109 records · Page 6Linked to original sources
PubMed1987

[Prostaglandin E1 in stage III and IV arterial occlusive diseases. results of a multicenter study].

In a controlled randomized trial at four centers, using a common protocol, 57 patients with advanced chronic arterial occlusive disease (21 in stage III, 36 in stage IV) were treated with prostaglandin E1 (PGE1) or adenosine triphosphate (ATP) for three weeks. Both substances were administered intraarterially over 60 min. Daily dose of PGE1 was 20 micrograms, of ATP 30 mg. Both produced a significant reduction in resting pain at the end of the treatment phase, in stage III significantly better with PGE1. There was also a clear reduction in the use of analgesics, significantly more so with PGE1. Healing or improvement of ulcers was significantly better with PGE1, while there was no significant differences between the two drugs as regards stage improvement. Three amputations had to be performed in the PGE1 group, nine in the ATP group, a significant difference. Side effects in the form of reddening, pain and swellings occurred in 15 patients of the PGE1 group and six of the ATP group. Final verdict by the treating doctor about the success of treatment was significantly more favorable for PGE1.

Adenosine Triphosphate↗
PubMed1987

Clinical effects of intravenous iloprost in patients with intermittent claudication.

In a randomized patient-blind study iloprost or hydroxy-ethyl starch 200/0.5 were given i.v. 5 h daily for 2 weeks to 24 patients suffering from severe intermittent claudication due to peripheral vascular disease. An increase in pain-free walking distance of more than 50% occurred in 6 of 11 patients after the iloprost infusions and in 7 of 12 patients after HES treatment. No significant effects on haemodynamic or clinical chemistry tests were observed.

Aged↗
PubMed1986

Tissue concentrations of ofloxacin in necrotic lesions in patients with peripheral vascular disease and in diabetics.

In a pilot study six patients (three diabetics with gangrenous lesions of the lower limbs, mean age 74 years, three patients with peripheral vascular disease stage IV according to Fontaine, mean age 70 years) were treated with 200 mg ofloxacin orally b.i.d. The tissue concentrations of ofloxacin in the necrotic material (1.6 to 6.4 mg/kg) were in the same range as the plasma levels (2.3 to 5.9 mg/l) or even higher. In conclusion, besides local therapy, ofloxacin seems to be effective in the systemic treatment of infected necrotic and gangrenous lesions.

Aged↗
PubMed1985

[Risk profile in peripheral arterial occlusive disease].

In numerous studies it has been established that risk profiles of coronary heart disease (CHD) and peripheral vascular disease (PVD) are different. There is no doubt about nicotine++ consumption as the most protective factory of PVD. In order of significance arterial hypertension, hyperlipoproteinemia, diabetes mellitus und reduced physical training are further risk factors. In contrast to CHD, the importance of LDL-cholesterin as arteriosclerotic factor is much lower in PVD while high level of triglyceride is an autonomous risk factor of PVD, as well as physical immobility. In the present review, the different penetrance of risk factors for individual vascular regions are described.

Arterial Occlusive Diseases↗
PubMed1985

[Effect of physical training on blood flow properties in patients with intermittent claudication].

Abnormal blood flow in patients with intermittent claudication can be normalized by physical training. We found a decrease in blood viscosity with a decrease in the erythrocyte-aggregation tendency and significant simultaneous improvement in erythrocyte filtrability. Improvement in these haemorheological properties led to a significant increase in physical performance after training. This positive result can be obtained by regular physical training; the application of rheologically effective medicaments is not necessary.

Adult↗
PubMed1985

Training-induced changes in serum lipids, fat tolerance, and adipose tissue metabolism in patients with hypertriglyceridemia.

Ten males (mean age 44 years) with primary hypertriglyceridemia were trained for 4 months 3 times/week for 1-h sessions. Eleven patients with similar physical characteristics and hypertriglyceridemia served as controls. Serum was assayed for TG and cholesterol (CH) and the various lipoprotein fractions, apoprotein A-I, glucose, insulin, and C-peptide. The removal of TG from the circulation was estimated by the Intralipid test. An open fat biopsy was taken and the incorporation and esterification of [14C]palmitate and glycerol release were measured in vitro. Following endurance physical training, serum TG and VLDL-TG decreased by 25 and 27%, respectively. No changes were observed in total CH and CH in the lipoprotein fractions or in apoprotein A-I. Fat tolerance increased slightly (+8%) whereas the incorporation of labelled palmitate into adipose tissue was reduced by 16%. The diminished incorporation was concomitant with a reduction in the esterification of fatty acids to TG (-29%). Enhanced removal of TG may contribute to the lowering of serum TG. The skeletal muscle is probably responsible for this adaptation, whereas the uptake of TG into adipose tissue is diminished.

Adipose Tissue↗
PubMed1984

[Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].

The efficacy of naftidrofuryl ( Dusodril ) for treatment of stage II arterial occlusive disease was evaluated in a controlled multi-centre study in a total of 104 out-patients with angiographically documented localization of occlusion. The therapeutic effect was assessed over three months by measurements of walking distance using standardized treadmill conditions. Further parameters were venoocclusive plethysmography and Doppler ultrasonography measurement of pressures. The complaint-free walking distance increased significantly during daily application of 600 mg naftidrofuryl orally (n = 54) during the 12-week assessment period when compared to the placebo group (n = 50). Taking the intraindividual variability of 17.2 m in assessment of walking distance into account, the increase of painless walking of 93 m after treatment for 12 weeks in the active-drug group is considered the result of treatment-induced increased performance.

Administration, Oral↗
PubMed1984

[Modification of blood coagulation and fibrinolysis through physical activity].

Physical conditioning appears to protect against the development of vascular disease. Although physical training often evokes favorable alterations in established cardiovascular risk factors, such as plasma lipids and lipoproteins, the metabolic sequelae of regular exercise that mediate a reduction in the risk of cardiovascular disease remain incompletely understood. Studies in recent years have shown physical training to have beneficial effects on blood coagulation and fibrinolytic activity. On general the data support the concept that blood clotting is potentiated by exercise. Mechanisms involved are an increased release of thromboplastine of tissue, increased coagulation with lactate accumulation during exercise, increased concentrations of plasma proteins owing to hemoconcentration, increased concentrations of specific clotting factors, e.g., Factor VIII and fibrinogen, and an alteration in platelet count and platelet function. The acceleration in coagulation is less in the well-exercised individual. There is evidence that an epinephrine mediated mechanism is responsible for the difference between individuals who have a lot of exercise and those who do not. Fibrinolytic activity seems to increase with exercise in a linear relationship with the heart rate during physical activity. An enhancement of the plasma fibrinolytic activity, stimulated experimentally by thrombotic stress such as venous occlusion, could be an important mechanism in the beneficial effect of habitual physical exercise on the risk of cardiovascular disease.

Arteriosclerosis↗